ML193
ML193 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 乙醇中≤0.1mg/ml；DMSO中≤2mg/ml；二甲基甲酰胺中≤3mg/ml |
| 形态 | 结晶固体 |
| 颜色 | 米白色至黄色 |
| InChIKey | HTSLEZOTMYUPLU-UHFFFAOYSA-N |
| SMILES | N1C2C(=CC(C)=CC=2C)C(C(NC2=CC=C(S(NC3ON=C(C)C=3C)(=O)=O)C=C2)=O)=CC=1C1=NC=CC=C1 |
ML193 用途与合成方法
IC50: 221 nM (GPR55)
ML-193 (0.01-100 μM; pretreated for 15 min) inhibits β-arrestin trafficking induced by L-α-lysophophosphatidylinositol (LPI, 10 μM) and ML186 (1 μM) with IC
50
s of 0.22 μM and 0.12 μM, respectively.
ML-193 (0.01-10 μM; pretreated for 30 min) decreases the LPI-mediated ERK1/2 phosphorylation, with an IC
50
of 0.2 μM in U2OS cells.
ML-193 (5 μM; pretreated for 30 min) attenuates the GPR55 agonists induced increases in hNSCs proliferation rates.
ML-193 (5 μM; 10 d) attenuates the ML184-induced increases in hNSCs differentiation.
ML193 (1 and 5 µg/rat; intra-striatal at a rate of 1 μL/min) attenuates sensorimotor deficits and slip steps, increases motor coordination in PD rats.
| Animal Model: | Male Wistar rats (200-250 g) were induced experimental Parkinson by 6-hydroxydopamine (6-OHDA, 10 µg/rat) |
| Dosage: | 1 and 5 µg/rat |
| Administration: | Injected into the right striatum at a rate of 1 μL/min |
| Result: | Increased the time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats. |
ML193 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-110125 | 713121-80-3 | 1 mg | 300 | |
| 2026-06-05 | HY-110125 | ML193 | 713121-80-3 | 5mg | 600 |
